Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab plus TNT in high-risk locally advanced rectal cancer
NCT04340401Phase 2Unknown
- Sponsor
- Peking University Cancer Hospital & Institute
- Start
- May 2020
- Primary completion
- Jul 2020
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of camrelizumab in rectal cancer, sponsored by Peking University Cancer Hospital & Institute. Status: unknown.
02
Drugs
camrelizumab
03
Conditions
rectal cancer
Beyond the preview
Go deeper on NCT04340401.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04340401.